Orexia Therapeutics has an emerging pipeline of assets comprised of novel small molecules and peptides which activate orexin receptors. While our primary focus is Narcolepsy Type 1, we are also conducting research to explore the role of orexin in a broad range of therapeutic indications, to maximize the number of patients who will benefit from therapies based on orexin activation.
Discovery Lead-Op / IND-enabling Phase 1 Phase 2 Phase 3
Oral OX2R agonistIndication: Narcolepsy Type 1
Intranasal OX2R agonistIndication: Narcolepsy Type 1
Orexia Therapeutics is also working on next generation differentiated orexin agonists and modulators which are currently in the discovery stage